First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|February 18, 2019
EGATEN for Treatment of Fascioliasis
Author(s)Drew Boxler
Anthelmintic tablet for patients 6 years of age and older.
Advertisement
EGATEN™ (triclabendazole, Novartis)
Indications: treatment of fascioliasis in patients six years of age or older
Dosage:
- 2 doses of 10 mg/kg given 12 hours apart in patients age 6 years of age or older
- Take orally with food
- Can be swallowed whole, divided in half and taken with water, or crushed and administered with applesauce
- âRound dose upwards if unable to adjust exactly
Contraindications: known hypersensitivity to triclabendazole, other benzimidazole derivatives or any of the excipients in EGATEN
Advertisement
Related to this article
A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.
Availability will vary by state, and a pharmacy professor says cost barriers can keep families from getting vaccinated.
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Advertisement
Advertisement